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English summary 
Evidence that opioids can produce analgesia outside the central nervous system has accumulated the past 
decades. However, in most human studies local administration of opioids in somatic tissue, especially the 
intra-articular injection of morphine, has been investigated. Thus, thorough information regarding local 
opioid analgesia on visceral peripheral opioid receptors in humans is lacking. Opioid antagonists are 
increasingly used to neutralize gastrointestinal side effects of opioids. However, antagonists may decrease 
the potential local analgesic effects of opioids exerted via peripheral opioid receptors in the gut. Thus, 
investigation of the effects of such antagonists is warranted. Altogether, this information may be clinically 
relevant, since pain originating from the gut is one of the most common reasons why patients are referred to 
gastrointestinal clinics. The overall objectives of this Ph.D. thesis were, by means of an experimental pain 
model, to assess the peripheral effects of morphine after local administration in the rectum and compare 
these peripherally mediated effects to the centrally mediated effects; and further to assess the peripheral 
effects of methylnaltrexone, a peripherally acting mu-antagonist (study II). Prior to this, a dose escalation 
study (study I) was performed to optimize the study design with regards to both dose and quantitative 
sensory tests, to assess the safety and tolerability and to attain more detailed information of the 
pharmacokinetic profile of morphine after rectal administration. The study population in both studies was 
healthy male participants. 
    Based on two different experimental pain studies, this Ph.D. thesis (1) assessed which of two quantitative 
sensory test that should be applied in study II; (2) assessed the safety and tolerability of three clinically 
relevant rectal doses of morphine; (3) evaluated an optimal morphine dose to use in study II;  (4) described 
the population pharmacokinetics of rectally administered morphine; (5) investigated the peripheral effects of 
morphine before and after blocking of the peripheral µ-opioid receptors with the peripherally restricted µ-
antagonist methylnaltrexone; (6) investigated the central analgesic effects of morphine; which included an 
assessment of the morphine effect on three objective measures (pupil diameter, prolactin secretion, and 
resting encephalography) and (7) compared the changes in these objective measures to subjective analgesia 
using a quantitative sensory test. 
    The findings from the dose escalation study showed, mechanical muscle stimulation was most sensitive to 
morphine analgesia compared with thermal skin stimulation; and that rectally administered liquid morphine, 
in the dosing range of 10-20 mg, was safe and well tolerated. A model was further developed to describe 
population pharmacokinetics of rectally administered morphine. The bioavailability was estimated to 24% 
which corresponds well to bioavailability after oral administered morphine. Based on the findings from this 
study, a morphine dose of 30 mg was considered to be optimal for study II. 
    No peripheral analgesic effect of morphine was found. On the other hand, methylnaltrexone may have 
exerted a local effect on rectal distensions and thereby appeared to improve analgesia. Methodological 
shortcomings in the experimental study design may have contributed to the lack of peripheral morphine 
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effects and thus, a peripheral effect of morphine on rectal pain during e.g., inflammation cannot be excluded. 
However, a 30 mg rectal morphine dose proved to be adequate to induce centrally mediated analgesia, which 
was manifested as an increase in tolerance to mechanical muscle pressure, a decrease in pupil diameter 30 
minutes after dosing and an increase in prolactin concentration which followed 45 minutes after morphine 
administration. An effect was also seen on resting EEG, however it was considerable delayed compared to 
the onset of analgesia. Thus, only pupil diameter and prolactin concentration proved to be sensitive objective 
measures of central morphine analgesia. However, pupil diameter is the most feasible objective measure. 
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Danish summary 
Gennem de seneste årtier har flere videnskabelige studier påvist, at opioider kan virke smertestillende 
udenfor centralnervesystemet. Humane studier har dog fortrinsvist undersøgt den lokale smertestillende 
effekt i somatiske væv. Viden om opioiders smertestillende effekt via opioid receptorer i tarmen er således 
mangelfuld. Opioid antagonister anvendes i stigende grad til at neutralisere gastrointestinale bivirkninger af 
opioider. Antagonister kan dog potentielt reducere en lokal smertestillende effekt af opioider via opioid 
receptorer i tarmen. En undersøgelse af effekterne af sådanne antagonister er således ønsket. Information om 
lokal smertestillende effekt kan være klinisk relevant, da smerter der stammer fra tarmen er en af de mest 
hyppige årsager til, at patienter henvises til gastrointerologiske afdelinger.  
    Det overordnede formål med dette Ph.D. projekt var, at undersøge den lokale smertestillende effekt af 
morfin efter administration i endetarmen samt at sammenligne disse lokale smertestillende effekter med 
smertestillende effekter medieret via centralnervesystemet. De lokale smertestillende effekter blev undersøgt 
før og efter blokering af opioid receptorer i tarmen. Til dette formål blev antagonisten methylnaltrexon 
anvendt. For at undersøge de lokale smertestillende effekter af morfin, blev der udført et eksperimentelt 
smertestudie (studie II) der involverede anvendelse af forskellige kvantitative smertetests. Eksempelvis blev 
de lokale smertestillende effekter undersøget ved hjælp af mekanisk smertestimulering af tarmen. Forud for 
dette studie, blev der udført et dosis eskaleringsstudie (studie I), der inkluderede to forskellige kvantitative 
smertetest, mekanisk muskel smerte og termisk hud smerte. Studie I blev udført for at optimere 
studiedesignet med hensyn til valg af både morfin dosis og smertetest samt for at vurdere sikkerheden i 
forbindelse med rektal administration af morfin. Et andet formål med dosis ekskaleringsstudiet var, at opnå 
en mere detaljeret viden om morfins farmakokinetik efter rektal administration. Studie populationen var 
raske mandlige forsøgspersoner.  
    På baggrund af disse to eksperimentelle smerte studier, vurderede det nærværende Ph.d. projekt (1) 
hvilken af de to smertetest der skulle anvendes i studie II; (2) sikkerheden af tre klinisk relevante rektale 
morfin doser samt hvor godt forsøgspersonerne tolererede dem; (3) hvilken morfin dosis der skulle anvendes 
i studie II; (4) populations farmakokinetikken af rektalt administreret morfin; samt (5) undersøgte de lokale 
smertestillende effekter af morfin før og efter blokering af lokale opioid receptorer i tarmen med 
antagonisten methylnaltrexon; (6) evaluerede morfins virkning i central nervesystemet; og herunder 
vurderede ændringerne i tre objektive mål for aktivering af centralnervesystemet (pupildiameter, prolactin 
sekretion og elektroencefalografi) og (7) sammenlignede ændringerne i disse objektive mål med den 
subjektive smertestillende effekt. Den subjektive smertestillende effekt blev undersøgt ved hjælp af en 
kvantitativ smertetest.  
    Resultaterne fra undersøgelserne viste, at morfin doser på 10-20 mg var sikre og veltolererede. Der blev 
udviklet en model til at beskrive populations farmakokinetikken efter rektal administration. Ud fra denne 
model blev biotilgængeligheden estimeret til 24 %, hvilket svarer til morfins biotilgængelighed efter oral 
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administration. Ud fra fundene i studie I blev det yderligere vurderet, at 1) mekanisk muskel smerte samt 2) 
morfin dosis på 30 mg skulle anvendes i studie II.  
    Der blev ikke fundet en lokal smertestillende effekt af morfin. Til gengæld kunne forsøgspersonerne 
tolerere mere smerte efter blokering af de lokale opioid receptorer. Methylnaltrexon syntes således at 
forbedre den smertestillende effekt. Metodologiske mangler i det eksperimentelle studie design kan have 
bidraget til den manglende lokale smertestillende effekt af morfin. En lokal smertestillende effekt kan derfor 
ikke udelukkes ud fra fundene i det nærværende studie.  
    En morfin dosis på 30 mg viste sig at være tilstrækkelig til at fremkalde centralt medieret smertestillende 
effekt. Dette manifesterede sig ved at forsøgspersonerne tolerede mere muskel smerte samtidig med at pupil 
diameteren blev mindre. For begge mål indtraf effekten 30 minutter efter dosering. Morfin inducerede også 
en stigning i prolactin koncentration 45 minutter efter dosering. Derforuden blev der observeret en effekt på 
EEG, dog først 120 minutter efter dosering. Det var kun pupil diameter og prolactin koncentration der viste 
sig at være følsomme objektive mål for central morfin analgesi. Pupil diameter anbefales dog som objektivt 
mål for aktivering i centralnervesystemet, når et simpelt objektivt mål er ønsket. 
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1 General introduction 
1.1 Pain  
Pain is an essential function of the nervous system, which provides the body with a warning signal of 
potential or actual injury and is thus, an integral part of the defense mechanisms required for survival. 
According to the taxonomy of International association for the study of pain (IASP), nociception is defined 
as: “The neural process of encoding noxious stimuli” whereas pain is defined as: “An unpleasant sensory 
and emotional experience associated with actual or potential tissue damage, or described in terms of such 
damage”(1). Pain is a subjective experience, it is always unpleasant, each individual learns the application of 
the word through own experiences and due to the unpleasantness of the pain, it also has an emotional aspect. 
Thus, it is a highly complex and multidimensional experience comprising three components: 1) The sensory-
discriminative component, 2) The affective-motivational component and 3) The cognitive evaluative 
component (2). The sensory-discriminative component relates to the ability to locate pain, to identify the 
pain modality and to assess the intensity. The motivational-affective component on the other hand, considers 
the emotional aspect of the pain experience e.g. fear and anxiety. The cognitive evaluative component relates 
to the evaluation and interpretation of the pain experience. This is for instance influenced by anticipation and 
memory of the experience (2).  
    Pain is classified in nociceptive pain, neuropathic pain and pain due to sensitization, however only 
nociceptive pain is relevant in the context of this thesis. There are two distinct types of nociceptive pain; 
somatic and visceral. Somatic pain refers to pain that originates from skin, muscle or bone while visceral 
pain originates from internal organs (viscera). Visceral pain has several distinct characteristics that 
differentiate it from somatic pain. Somatic pain is well localized and well characterized by patients and in 
research in animal and humans. In contrast, visceral pain is deep, dull, diffuse and thus, poorly localized. In 
addition, visceral pain is accompanied by motor and autonomic reflexes e.g. nausea, vomiting and diarrhoea 
(3). Another particularity is that visceral pain can be referred to somatic structures remote from the stimulus 
(4). In contrast to somatic pain the mechanisms causing visceral pain are poorly understood. To optimize the 
treatment of visceral pain, it is essential to improve the present knowledge of the mechanisms causing pain 
and of the pharmacological mechanisms of action of analgesics. 
 
1.1.2 Impact of pain 
Considering the unpleasantness of the pain experience and the emotional aspect, it is not a surprise that 
chronic pain negatively affects many aspects of quality of life, daily activities, social and working lives (5,6) 
and patients suffering from chronic pain frequently display comorbid depression (7). According to a large 
survey (N=46394) performed in Europe and Israel, chronic pain of moderate to severe intensity affects 19% 
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of the adult population. Few patients suffering from chronic pain are managed by pain specialists and almost 
half do not receive adequate pain management (8).  
    Among the different types of pain, chronic pain originating from viscera is one of the most common 
causes of morbidity in the general population (4). Thus, chronic visceral pain represents an immense 
challenge for public health and constitutes a considerable socioeconomic burden as a result of medical 
expenses, hospitalization, and job absenteeism (5,6). The enticement for pain research is clear when 
considering the number of people suffering from chronic visceral pain.  
 
1.2 The pain system 
The somatosensory system is a complex sensory system, made up of a number of different receptors, 
including thermoreceptors, photoreceptors, mechanoreceptors and chemoreceptors. It can be divided into at 
least four distinct modalities: touch, propioception, temperature and nociception. Each modality has its own 
receptors, fibers and pathways. Nociception begins in the periphery where sensory fibers detect mechanical, 
thermal or chemical changes above a certain threshold. Before pain can be perceived, the nociceptive signal 
goes through distinct processes referred to as transduction, transmission and modulation (9). Transduction is 
the process by which the stimuli (mechanical, thermal or chemical) is transduced into electrical energy and 
once the electrical energy reaches threshold value an action potential is induced. Transmission refers to 
transport of the signal from the periphery. The signal is passed along the axon of the neuron into the spinal 
cord and further to higher brain centres. Before reaching the cortical regions in the brain, modulation of the 
nociceptive signal takes place. Modulation will result in either an inhibition or a facilitation of the neuronal 
activity. Essentially, the nociceptive signal reaches the cortical regions where pain perception is generated 
(10-12).  
 
1.2.1 The primary afferent 
Primary afferent fibres are sensory neurons which respond to potentially harmful stimuli. Their cell bodies 
are located in the trigeminal (the face) and dorsal root ganglia (the body). Primary afferent fibres have a 
peripheral and central axonal branch; the peripheral axonal branch innervates their target organ, while the 
central axonal branch terminates in the dorsal horn of the spinal cord. The fibres terminate in so called “free 
nerve endings” where the noxious stimuli are transduced into electrical signals.  The terminal end of the 
axonal branches is referred to as either the peripheral- or central terminals (11). There are three main types of 
sensory fibres in the periphery: Aβ-fibres, Aδ-fibres and C-fibres. They have different properties (e.g. size, 
conduction velocity and presence/lack of myelin sheath) and can be characterized according to the type of 
stimuli they respond to e.g. chemical, thermal or pressure; or according to their tissue localization e.g. skin, 
muscle or viscera (10,12). These properties allow them to selectively respond and transmit sensory 
information of an intensity that is tissue threatening or damaging. The conduction velocity is directly 
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correlated to their diameter and degree of myelination (10-12). Aβ-fibres have large diameters and are highly 
myelinated. Thus, they conduct action potentials at high speed. Generally, these fibres have a low activation 
threshold and are responsible for the perception of non-noxious stimuli. Sensory fibres that respond to 
noxious stimuli (Aδ- and C-fibres) are referred to as nociceptors. These fibres conduct relatively slowly, 
being only lightly myelinated or unmyelinated. Compared to Aβ-fibers, Aδ-fibres have a smaller diameter, 
have higher thresholds for activation, are thinly myelinated and thus, are slower conducting. These fibres 
respond to chemical, thermal and mechanical stimuli (11). Aδ-fibres fibres are responsible for “first pain” 
which is rapid in onset, well localized and sharp or pricking character. The majority of C-fibres are 
polymodal and respond to thermal and mechanical stimuli while some C-fibres respond only to a specific 
type of stimuli. C-fibres have the highest thresholds for activation. Due to the light or non-myelination of the 
axon, these nociceptive fibres can only allow an action potential to travel at low speed, making them the 
slowest conducting nociceptors. As a result of their slow conduction velocity they are responsible for 
“second pain” which is characterized by a dull, diffuse and throbbing sensation (12). A group of 
unmyelinated nociceptors do not respond to stimuli unless they are activated by inflammation. They are 
usually referred to as “silent nociceptors” (11).  
 
1.2.2 Sensory transmission  
The recruited nociceptors (primary neurons) transmit the nociceptive signal from the periphery through the 
dorsal root ganglion to the dorsal horn of the spinal cord where the central terminal of the primary afferent 
fibres terminates. The dorsal horn is laminated in physiologically distinct layers (lamina) that extend from 
superficial to deep dorsal horn (11,12). Non-noxious Aβ-fibres primarily terminate in lamina III-V. C-fibres 
project superficially to lamina I-II while Aδ-fibres project to lamina I and V (10,11) (Fig. 1). After reaching 
the designated lamina, the primary neurons project to secondary neurons and the first synaptic relay takes 
place (Fig. 2). In addition, the primary neurons make synaptic contact with inhibitory and excitatory 
interneurons in the dorsal horn. These interneurons are involved in the processing of the nociceptive signal 
before the secondary neuron project to higher brain centres. The secondary neurons can be divided into 1) 
nociceptive-specific (NS) neurons and 2) Wide-Dynamic-Range (WDR) neurons. NS neurons are primarily 
found in lamina I-II and respond to nociceptive stimulation mediated by Aδ- and C-fibres or Aδ-fibers alone. 
On the other hand, WDR neurons have the capacity to respond to both innocuous and noxious stimuli as they 
receive input from Aβ-, Aδ- and C-fibres. Their response is graded according to stimulus intensity (9,12). 
Primary afferent neurons release a variety of neurotransmitters e.g. glutamate, substance P and calcitonin 
gene-related peptide from the central terminal. The released neurotransmitters mediate nociceptive signalling 
by activating receptors on secondary neurons in the dorsal horn (e.g. neurokinin, α-amoni-3-hydroxy-5-
methyl-4-isoxazolepropionic acid and N-methyl-D-aspartat) (10). The received information is instantly 
projected by the secondary neurons to higher brain centres, primarily the thalamus. 
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Fig. 1: 
Recruited nociceptors transmit the nociceptive signal from the 
periphery through the dorsal root ganglion to the dorsal horn of 
the spinal cord. The dorsal horn is laminated in physiologically 
distinct layers (lamina) that extend from superficial to deep 
dorsal horn. Non-noxious Aβ-fibers principally terminate in 
lamina III-V. C-fibers project superficially to lamina I-II while 
Aδ-fibers primarily project to lamina I and V. 
 
 
For a large proportion of the afferents, a second synapse takes place in different nuclei of the thalamus.  
Secondary neurons may also make synapses with neurons in different nuclei of the brainstem – areas which 
are involved in endogenous mechanisms that inhibit or facilitate the nociceptive signal (descending 
modulation) (9). After these two synaptic relays, the tertiary neurons from the thalamus then project to the 
primary and the secondary somatosensory cortex, but also to limbic structures such as anterior cingulate 
cortex and amygdala (9,12). These cortical regions are collectively referred to as the “brain matrix” (13). 
Modulation of spinal nociception originates from various brain regions. The periaqueductal gray (PAG) and 
the rostral ventromedial medulla (RVM) are among the best described (14).  
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Fig. 2: Sensory transmission 
Primary afferent nociceptors (primary neurons) in the 
periphery (e.g. visceral afferents) transmit the nociceptive 
signal from the periphery (e.g., pain following rectal 
distention) through the dorsal root ganglion to the dorsal 
horn of the spinal cord where the central terminal of the 
primary afferent fibers terminates. The primary neurons 
project to secondary neurons and the first synaptic relay 
takes place. The received information is instantly 
projected by the secondary neurons to higher brain 
centers. For a large proportion of the afferents, a second 
synapse takes place in different nuclei of the thalamus but 
also with different nuclei of the brainstem. Tertiary 
neurons from the thalamus then project to the primary and 
the secondary somatosensory cortex, but also to limbic 
structures 
 
 
1.2.3 Innervation of the gastrointestinal tract 
The gastrointestinal (GI) tract is innervated by sensory neurons in the central nervous system (CNS) 
(extrinsic afferents) as well as its own integrated network of sensory neurons (intrinsic primary afferent 
neurons), interneurons and motor neurons which form the enteric nervous system (ENS).  The ENS is 
embedded in the gut wall – and extends from the esophagus to the anus. The ENS motor neurons can 
generally be divided into to two groups: 1) muculomotor neurons that innervate the muscularis externa and 
muscularis mucosa; and 2) secretory neurons that innervate the intestinal secretory glands. Two major 
nervous plexuses; the myenteric and the submosal plexuses exist. The myenteric plexus is localized between 
the longitudinal and the circular muscle layers while the submucosal plexus, as indicated by the name, is 
located in the submucosa. These two plexuses are responsible of different functions; the myenteric plexus for 
controlling the motor activity within the gut while the submucosal plexus is responsible for secretory and 
absorptive activities (15,16).  
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1.3 Pharmacological pain management  
Successful pain management depends on selecting the appropriate drug substance, the correct dose and 
administers it at the right time while carefully balancing analgesia against side effects. In an attempt to 
outline this, the “analgesic ladder” was introduced by the World Health Organization (WHO) (17). The 
analgesic ladder is a three step approach to the use of analgesics according to pain severity. The concept was 
originally intended for management of cancer pain; but has been extrapolated to non-malignant pain (9). The 
analgesic drugs should be introduced promptly when pain arise in increasing potency and titrated until the 
patient is free of pain. The approach is arranged in the following order: step 1) Non-opioid analgesics 
(aspirins or NSAIDs), then step 2) weak opioids (e.g., tramadol or codeine) and then if necessary step 3) 
strong opioids (e.g. morphine). Adjuvant drugs are recommended to calm fears and anxiety and to treat some 
pain disorders such as chronic pancreatitis and neuropathic pain. According to WHO, this drug strategy is 
inexpensive and 80-90% effective if the drugs are administered proactively every 3-6 hours as opposed to 
“on demand” administration. Non-opioid analgesics and adjuvant drugs are beyond the scope of the present 
thesis and thus, focus will on opioids, in particular morphine. 
 
1.3.1 Opioids 
The term “opiate” is used to describe naturally occurring alkaloids derived from the opium poppy plant. The 
term ”opioid” covers the description of all substances both endogenous and exogenous, which exert their 
actions on opioid receptors. Morphine is usually considered the “gold standard“ among exogeneous opioids. 
The opioid system consists of four opioid receptors (specific proteins): mu (μ), delta (δ), kappa (κ) and 
opioid-like receptor 1(18). Opioid-like receptor 1 displays 65 % sequence homology to the other receptors 
(19). All receptors are G-protein-coupled (Gi or Go) and share the similar seven transmembrane helical 
structure with three intracellular and extracellular loops, an extracelluar N-terminus and intracellular C-
terminus. Opioid receptors are stimulated by endogenous opioids (i.e. endorphins, enkephalins and 
dynorphins) and can additionally be stimulated by clinically applied opioids (exogenous opioids). Most 
clinically relevant opioids exert their analgesic effect at the µ-receptor including the “gold standard” 
morphine. The majority of opioids are agonists, which interact with the opioid receptor and thereby produce 
an analgesic response. Pure agonists, such as morphine, are considered the most potent analgesics. 
Antagonists also bind to the opioid receptors, but exert no analgesic response and importantly, they can 
antagonize the effect of agonists.  
 
1.3.1.1 Analgesic actions of opioids 
 Central opioid analgesia 
All opioid receptor types are expressed on neurons in the dorsal horn of the spinal cord and it is a key area of 
opioid action (14). After opioid binding to receptors on presynaptic terminals of Aδ- og C-fibers, a part of 
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the G-protein is released and it diffuses within the intracellular space to voltage gated ion-channels and to 
enzymes which can inhibit the voltage gated ion-channels. In brief, the comprehensive intracellular 
signalling involved in analgesia, essentially leads to an inhibition of calcium influx. This in turn leads to a 
decrease in the cyclic adenosine monophosphate. The overall effect is a reduced release of pain 
neurotransmitters such as glutamate, substance P and calcitonin gene-related peptide and thus, a decreased 
neuronal activity (Fig. 3). On postsynaptic terminals, the opioids inhibit potassium ion efflux which results in 
a decreased neuronal activity (18). Altogether, these processes ultimately lead to analgesia.  
 
 
 
 
 
 
Fig. 3: Over simplified illustration of opioid mechanisms of 
action at the presynaptic terminal. After opioid binding to 
receptors on presynaptic terminals (e.g morphine (MOR)), a 
part of the G-protein is released. The G-protein diffuses to 
voltage gated ion-channels and to enzymes which can inhibit 
the voltage gated ion-channels. In brief, the comprehensive 
intracellular signalling involved in analgesia, essentially leads 
to an inhibition of voltage dependent calcium channels and 
thereby a decrease in calcium influx. This in turn leads to a 
decrease in the cyclic adenosine monophosphate (cAMP). 
Consequently, the overall effect is a reduced release of pain 
neurotransmitters such as glutamate, substance P and 
calcitonin gene-related peptide and thus, a decreased 
neuronal activity. Red lines indicate inhibition. 
 
On the supraspinal level the most important and best studied sites of opioid action are the PAG and RVM 
although other supraspinal sites also support opioid analgesia (10,14). RVM sends projections to the dorsal 
horn along descending pathways. The µ-receptors are found in RVM where they play a principal role in 
opioid analgesia (14). The PAG sends projections to the RVM but does not project directly to the dorsal 
horn. Altogether, the projections terminate in the lamina relevant in the nociceptive processing. The net 
effect of these mechanisms is antinociception. The κ-receptors are distributed in the PAG although the 
primary opioid actions are produced by μ-receptors. Additionally, δ-receptors are found in the RVM, but 
their effects are not fully understood (18). The inhibition and the facilitation of the nociceptive transmission 
is the result of the activation on ON- and OFF cells in the RVM. When OFF-cells are activated it results in 
inhibition of pain while activation of ON-cells facilitates pain (14).  
 
19 
 
Peripheral opioid analgesia 
For decades, opioids were thought to act only via interaction with supraspinal and spinal opioid receptors. 
However, this notion has been challenged and today it is well accepted that antinociception can not only be 
produced by opioid receptors located in the CNS, but also via opioid receptors on peripheral sensory neurons 
(20). The peripheral analgesic activity is exerted without activation of CNS opioid receptors and is thus 
devoid of centrally mediated side effects (see section 1.3.1.2). In addition it has been suggested that 
peripheral opioid analgesia is less sensitive to development of tolerance (21). It is well established that 
opioid receptors are synthesized in the DRG are transported to central as well as peripheral nerve terminals 
(21). In humans, as in animals, opioid receptors are located on peripheral sensory neurons of small, medium 
and large size (22). Although opioids with a preference for μ-receptors are thought to be the most potent 
inducers of peripheral analgesia, δ- and κ-ligands are also believed to contribute (20). Evidence that 
peripheral antinociceptive effects may be mediated by peripheral opioid receptors has emerged in the past 
two decades. In humans, potent analgesic effects after local application have been reported after knee 
arthroscopy (23-26) and in patients undergoing dental surgery (27,28). However, the most extensively 
investigated local application is the intra-articular injection of morphine (reviewed in reference (29)). It has 
been demonstrated that peripheral analgesia is more pronounced in the presence of inflammation (30-34). An 
array of complex mechanisms has been suggested to contribute to the antinociceptive efficacy in inflamed 
tissue; although one major underlying mechanism is up-regulation of opioid receptors (20).  
    Peripheral opioid receptors (µ, δ and κ) have also been found in the gut, where they potentially exert a 
local effect on pain (35-37). Preclinical studies suggest that noxious visceral stimuli can be inhibited by κ-
opioid agonists at the peripheral site (38-42). Supporting this; a novel peripheral restricted κ-agonist, ADL 
01-0101 produced analgesia in chronic pancreatitis patients. The analgesic response was not associated with 
centrally mediated side effects, which support that the effects were peripherally mediated (43).  
    The discovery of opioid receptors in the periphery has stimulated research directed at developing 
peripherally active opioids without centrally mediated side effects. Hydrophilic compounds with restricted 
capability to penetrate the blood-brain-barrier have been common approaches. Examples of such compounds 
include the μ-agonist loperamide, which is originally intended for the treatment of diarrhoea, and 
asimadoline, a κ-agonist (20). The aforementioned peripheral restricted κ-agonist, ADL 01-0101, is an 
example of promising novel compounds (43). However, ADL 01-0101 has apparently not yet entered the 
market. Similarly, another novel peripheral restricted κ-agonist, CR665, had a selective effect on visceral 
pain, when compared with oxycodone in a multi-tissue experimental human pain model (44). However, 
centrally mediated side effects were reported, suggesting that CR665 is not fully peripherally restricted. The 
results from these studies support the hypothesis that opioid receptors are expressed in human visceral 
afferents and that analgesia can be produced in the periphery. 
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1.3.1.2 Opioid induced side effects 
Opioid-induced analgesia can unfortunately be accompanied by an array of side effects. These side effects 
are related to the binding of receptors involved in other functions and are peripherally and/or centrally 
mediated (45). Common centrally mediated side effects include somnolence, sedation, mental clouding, 
mood effects (euphoria or dysphoria) and more rarely, respiratory depression. In addition, long-term use of 
opioid analgesics is associated with clinically relevant rates of abuse or addiction (46,47). 
    Binding of opioids to peripheral opioid receptors in the myenteric and submucosal plexuses in the gut 
results in increased tone, dysmotility, enhanced absorption of fluids and decreased fluid secretion. In the 
clinic, these effects are manifested as opioid-induced bowel dysfunction (OIBD), where symptoms such as 
reflux, abdominal distension and constipation are prevalent (15,16). OIBD rarely disappears during the 
course of treatment (48) and pharmacological interventions include laxatives (bulk agents, stool softener, 
stimulants, enemas) as first-line treatment. The next step in the treatment pathway is formulations containing 
opioid antagonists with effects restricted to the periphery (e.g. slow release naltrexone or methylnaltrexone) 
(16,49). Other common gastrointestinal side effects include nausea and vomiting (50) although, the majority 
of patients develop tolerance to the central mediated nausea and vomiting within the first week of treatment 
(48). Although opioids do provide effective analgesia for many, treatment outcomes are variable (51). For 
some patients, chronic treatment with opioids may be ineffective and the side effects may persist and even 
become intolerable. This hampers patient recovery and limits the clinical usefulness of the opioids (47,51).  
     
1.3.1.3 Morphine  
Morphine was the first natural opium alkaloid to be isolated from the opium poppy plant (papaver 
somniferum). Morphine is a µ-agonist and for decades morphine has been the most important analgesic drug 
to alleviate moderate to severe acute and chronic pain; and it remains the gold standard against which new 
(and existing) analgesic drugs are compared (52,53). Morphine can penetrate the blood-brain-barrier (a 
membrane that tightly segregates the brain from the blood) but due to its low lipid solubility, it passes slowly 
(53).  
 
Administration 
Morphine can be administered by different routes including oral, rectal, subcutaneous, intravenous, epidural 
and intrathecal routes. However, oral administration is considered mainstay for pain management due to its 
simplicity, convenience and economy (52). Oral administration is not viable in patients with conditions such 
as severe nausea, vomiting, dysphagia, gastrointestinal obstruction, intolerance to oral morphine or mental 
confusion and alternative routes of drug administration may be required (52,54). The rectal route offers an 
alternative to the oral route and is non-invasive, painless and cheap. The pharmacokinetics has been 
investigated after different rectal formulations (tablets, suppositories, solutions and hydrogel) (55-65). 
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Results from previous studies indicate that the level of analgesia achieved after rectal administration is 
comparable to that of oral morphine (56,61,64-66). 
 
Metabolism, elimination and excretion 
The major metabolic pathway is the formation of morphine-glucuronides and the liver is the principal site of 
biotransformation (52,53). The glucuronidation, which occurs rapidly after morphine enters the blood (18) 
stream, is mainly catalyzed by UDP-glucuronosyl-transferase (UGT) isoenzyme UGT2B7 (52). Morphine-3-
glucuronide (approximately 50%) and morphine-6-glucuronide (approximately 10%) constitute the major 
metabolites (67). M3G is not considered to exert any analgesic actions; on the contrary M3G in high 
concentrations has been proposed to induce hyperalgesia (18,68). M6G has a strong affinity for the μ-
receptor. In general, the literature supports that M6G mediates analgesic effects by activating μ-receptors 
(67). However, the contribution to analgesia after morphine administration varies across studies (69-71). 
M6G penetrates of the blood-brain-barrier slower than does morphine. This is likely to be associated with the 
lower lipophilicity of M6G (67). The first-pass metabolism of morphine determines its systemic 
bioavailability. After oral administration, morphine is subject to an extensive first-pass metabolism and thus, 
resulting in a limited systemic bioavailability. The reported bioavailability after oral administration varies 
from 19% to 47% (53). The bioavailability after rectal administration has been reported to be 31-53 % 
depending on mode of administration (61,62,64).  The elimination half-life of morphine is approximately 2 
hours (52,53) and appears to be independent of administration route or formulation (53,72). Morphine and its 
metabolites are primarily eliminated via the kidney and excreted in urine, approximately 10% as unchanged 
morphine (52).  
 
1.3.2 Opioid antagonists  
Opioid antagonists act on opioid receptors and thereby antagonize the effect of agonists thus, ultimately 
preventing both the analgesia and side effects. Peripherally restricted μ-receptor antagonists, which only 
poorly penetrate the blood-brain-barrier (e.g. methylnaltrexone) or is fully first-pass metabolized in the liver 
(e.g slow release naltrexone) have been marketed to prevent the gastrointestinal adverse effects (16,49). 
However, only methylnaltrexone is relevant in the context of this Ph.D. project. Methylnatrexone is a 
peripherally restricted µ-opioid antagonist. It is a quartenary derivative of the antagonist naltrexone. 
Compared to naltrexone, methylnaltrexone has a greater polarity and lower lipid solubility as a result of 
adding a methyl group at the amine in its ring. Consequently, methylnaltrexone crosses the blood-brain- 
barrier poorly and therefore selectively blocks or reverses the undesired opioid induced peripherally 
mediated side effects in the gut without affecting centrally mediated analgesia (73,74). In the clinic, 
methylnaltrexone is used as a rescue medicine if standard laxative therapy has failed. It has been approved 
by European Medicines Agency (Europe) and Food and Drug Agency (USA) for treatment in adult patients 
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receiving palliative care (75). Methylnaltrexone is readily absorbed and Cmax is achieved approximately 0.5 
hours after subcutaneous injection (76), although the clinical effect (defaecation) can be seen after 5-10 
minutes (clinical observation). It has a plasma half life of approximately eight hours and is excreted via the 
kidneys and in the faeces. The most frequently observed adverse effects of methylnaltrexone are abdominal 
pain, nausea, flatulence and diarrhoea (74).  
 
1.4 Experimental human pain models 
As described in section 1.1, pain is a subjective experience and a highly individual perception. In patients 
suffering from chronic pain, the perception of pain is influenced by an array of factors including emotion, 
fear, anxiety, general malaise, cognitive responses and social consequences of the disease (2). Additionally, 
it has been demonstrated, that the pain experience does not correlate well with the severity of the 
pathological condition (77). Altogether, these individual psychological and physiological factors are a major 
shortcoming of clinical pain studies. Experimental pain models in healthy participants are advantageous as 
different pain modalities can be studied under standardized and reproducible laboratory conditions. This 
allow for a less confounded assessment (78). The main components of experimental pain models are 1) 
nociceptive stimulation and 2) the responses to these stimuli. In these models, the nature, intensity, 
frequency, location and duration of the stimulus can be controlled. The data obtained from experimental pain 
models are a psychophysical- and/or a biological response to the nociceptive stimulus (79). Different 
experimental stimulations have been established and the stimuli can be classified according to their physical 
properties into: electrical, thermal, mechanical, ischemic and chemical pain stimuli and stimulation can be 
performed in various tissues including muscles, bones, skin and viscera (reviewed in reference (80)). 
Stimulation modalities relevant for the present Ph.D. project are described in section 3.  
    The evoked pain sensation can be quantitatively assessed with subjective methods such as visual analogue 
scale (VAS), numerical rating scales or pain thresholds and qualitatively, e.g. by applying the McGill Pain 
Questionnaire (80,81). The stimulus-response relationship can hereby be investigated. The VAS is generally 
used for the sensory dimension of the pain experience. To assess the pain pathways or to elucidate 
underlying pain mechanisms, the subjective methods can be combined with objective methods such as the 
nociceptive withdrawal reflex, resting electroencephalography (EEG), cerebral evoked potentials and 
imaging techniques (e.g. fMRI and PET/SPECT) (80).  
 
1.4.1 Opioids in experimental pain models 
The induced pain stimulus can be modulated by administering an analgesic drug and assessment of the 
analgesic effect can subsequently be performed. To evaluate the analgesic effect in experimental pain 
studies, the following factors are to be considered when designing the trial: 1) The model, 2) the dose and 3) 
the dosing regimen and timing. Firstly, the model needs to activate the mechanisms and pain pathways 
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relevant for the given analgesic drug, and secondly, a drug dose that balances the analgesic effect and side 
effects is essential. Thirdly, it is relevant to consider the dosing regimen i.e. whether single or multiple doses 
are preferred (80,81). In addition, relevant time points for testing should be selected on the basis of the 
pharmacokinetic (PK) profile of the analgesic (80). If an opioid is the analgesic in question, as in study I and 
II, it is essential to bear in mind that they must cross the blood-brain-barrier and enter the CNS to exert their 
(primary) analgesic effect resulting in a lag-time to the onset of analgesia (81). Importantly, it is preferable to 
use relatively high doses when analgesic effects are investigated (80). 
 
1.4.2 Sex differences in pain perception 
The literature points towards differences in pain perception among men and women. On average, women 
tend to report more intense pain, longer pain duration and more frequent pain (82-84). Sex differences in 
perception of pain have been demonstrated in clinical and as well as in experimental settings (85,86). 
Possible explanatory factors for these differences may include biological, psychological, and cultural 
differences, divergent social role expectations and an individual’s past history (87). Biological sex 
differences, such as hormone variability, may provide a partial explanation to the observed sex differences in 
the response to experimental pain (88). Thus, the effect of the menstrual cycle on pain perception cannot be 
ignored. In experimental pain studies evoking somatic as well as visceral pain, females should therefore be 
examined in the same part of the menstrual cycle. This can be logistically challenging and further prolong 
the experimental study. Consequently, male participants are generally preferred over female participants. 
This was the case in the present Ph.D. project.  
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2 Objectives 
Evidence that opioids can exert analgesia outside the CNS has accumulated the past decades. However, in 
most of the human studies, local administration of opioids in somatic tissue has been investigated. This is 
particularly true for intra-articular injection of morphine. Thus, in-depth information regarding local opioid 
analgesia on visceral peripheral opioid receptors in humans is lacking. Opioid antagonists are increasingly 
used to neutralize gastrointestinal side effects of opioids. However, antagonists may decrease the potential 
local analgesic effects of opioids exerted via peripheral opioid receptors in the gut. Thus, investigation of the 
effects of antagonists is warranted. Altogether, this information may be clinically relevant, since pain 
originating from the gut is one of the most common reasons why patients are referred to gastrointestinal 
clinics. Thus, the overall objectives of this Ph.D. thesis were to assess the peripheral effects of morphine 
after local administration in the rectum and compare these peripherally mediated effects to the centrally 
mediated effects, and further to assess the effects of the peripherally acting µ-antagonist MNTX after 
subcutaneous administration. To optimize the study design (study II) and to attain more detailed information 
of the PK profile of morphine and M6G after rectal (liquid) administration, a dose escalation study (study I) 
was performed.  
 
2.1 Hypotheses and aims  
2.1.1 Study I 
It was hypothesized 1) that the dose escalation study with three clinically relevant doses that included two 
experimental pain stimuli would assess which of two quantitative sensory test, that would be most sensitive 
to morphine analgesia and therefore qualify to be used in study II; 2) that the three chosen doses of 10, 15 
and 20 mg morphine would prove to be well tolerated and safe; 3) that an optimal morphine dose for 
administration in study II could be selected on the basis of the results of study I, and finally that 4) 
population PK modelling would provide a more detailed understanding of the pharmacokinetic profile of 
morphine and M6G after rectal administration of morphine. 
 
The aims were therefore:  
1) To evaluate which of two quantitative sensory tests that should be applied in study II 
2) To assess the tolerability and safety of three clinically relevant doses of rectally applied morphine 
3) To evaluate an optimal morphine dose for study II 
4) To develop a population PK model of liquid rectal morphine and M6G  
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2.1.2 Study IIa 
It was hypothesized that an experimental model including both visceral and somatic stimulations would 1) 
enable differentiation between local visceral and central somatic effects after rectal administration of 
morphine and 2) demonstrate whether MNTX interacts with the local visceral effects.  
 
Accordingly the aims were: 
1) To investigate the peripheral effects of morphine before and after blocking of the peripheral µ-opioid 
receptors with MNTX  
2) To investigate the central effects of morphine 
 
2.1.3 Study IIb 
It was hypothesized that pupil diameter, prolactin concentrations and resting EEG would yield different 
sensitivity to morphine.  
 
The aims were therefore:  
1) To assess the effect of morphine administration on pupil diameter, prolactin secretion, and resting EEG  
2) Compare the changes in these objective measures to subjective analgesia using mechanically evoked 
muscle pain.  
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3 Methods and key results 
Section 3.1 and 3.2 gives a general introduction to the study conduct and the study population of both study I 
and II. This is followed by methods (section 3.3.1) and key results (section 3.3.2) for study I which is 
followed by methods (section 3.4.1) and key results (section 3.4.2) for study II. In the method sections, 
background information and rationale related to the different methods are described. 
 
3.1 Study conduct 
The present thesis is based on data from two experimental pain studies, referred to as study I and II. The 
studies were conducted in the research laboratory of Mech-Sense in Department of Gastroenterology & 
Hepatology, Aalborg University Hospital. Participants were informed in writing and then verbally before 
deciding to participate. After enrolment, at a separate screening session, the participants were instructed in 
and accustomed to the laboratory setting and the comprehensive pain testing procedures including the use of 
pain rating scales. These instructions were reinforced before each experimental test throughout the 
experiment using specific phrases to maximize reproducibility. To minimize bias, the experimental 
procedures were performed by the same two investigators. The experiments were conducted under controlled 
and quiet laboratory conditions devoid of interruptions and other disturbing factors.  
    Both studies were included in the same protocol. The protocol and the informed consent form were 
approved by The North Denmark Region Committee on Health Research Ethics, Denmark (N-20110077), 
The Danish Health and Medicines Authority (EudraCT identifier: 201100516920). It was further registered 
in clinicaltrialsregister.eu. The study was conducted in accordance with the Declaration of Helsinki and 
International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) guidelines. GCP guidelines 
are the ethical and scientific standards developed to guide researchers in conducting biomedical research.  
GCP is applied to all studies involving humans, regardless of the risk. These standards are intended to ensure 
that the rights and the welfare of the participant are protected and further; that the research study is 
scientifically sound (89). The study was monitored by the GCP unit at Aarhus and Aalborg University 
Hospitals.  
 
3.2 Study population 
Study I and II were both performed in healthy male participants of Northern European descent aged 18 to 65 
years (n=10 and n=15, respectively). Their health was verified by a thorough medical history and physical 
examination (including measurement of blood pressure and oxygen saturation). The examination was 
performed by a medical doctor. To be eligible for enrolment, it was further essential that the investigator was 
convinced that the participant: 1) Fully understood the contents of the study; 2) Was willing and able to 
comply with instructions; 3) Had the possibility to attend all the different experiments; and 4) Intended to 
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complete the study. Exclusion criteria were: 1) Allergy to study medication; 2) Participation in other medical 
studies fourteen days prior to the screening session; 3) Present and/or previous addictive behaviour observed 
in the participant or first degree relatives. Addictive behaviour is defined as abuse of alcohol, marijuana, 
opioids or other narcotics; 4) Present or previous chronic and/or pain related diseases; 5) Previous and/or 
present psychiatric diseases; 6) An expected need of medical treatment, surgery or hospitalization within the 
timeframe of the study; 7) Use of opioid analgesics and 8) Use of any type of analgesics 24 hours prior to a 
study visits. 
 
3.3 Study I 
3.3.1 Methods 
Study I was an open label, cross-over study with escalating doses of morphine hydrochloride. The study had 
four separate treatment arms, which were separated by a minimum of one week washout period. At the first 
study day, 2 mg morphine hydrochloride was administered intravenously. Intravenous administration of 
morphine allows for determination of the proportion of the rectal dose that is absorbed and thus, for 
calculation of the absolute bioavailability. If rectal morphine administration is warranted in the clinic, it is 
generally formulated as suppositories. However, the rate of dissolution or melting of the suppository, and 
hence the rate of absorption is highly variable between individuals. Consequently, a liquid formulation, 
where morphine is readily available for absorption, was applied in the present study. For safety reasons a 10 
mg dose was chosen as a start dose since the few published studies of liquid rectal administration (in adults) 
have used similar doses (59-61,90) (see Table 1, page 53). Study visits, dose escalations and mode of 
administration are summarized in Table 2. As a safety precaution the dose escalation was terminated if 
unacceptable adverse effects occurred in at least two participants. In this case, the dose would be adjusted to 
a lower dose; for example, if unacceptable adverse events were induced after administration of 20 mg rectal 
liquid morphine, a 15 mg morphine dose was thus to be used in study II. Unacceptable adverse effects were 
defined as unacceptable nausea, vomiting, dizziness, respiration depression or sedation. This assessment was 
conducted by a medical doctor.  
 
Table 2: Overview of study visits, mode of administration and doses.  
Study visit Mode of administration Drug Dose 
1 Intraveneous Morphine Hydrochloride 2 mg 
2 Rectal Morphine Hydrochloride 10 mg 
3 Rectal Morphine Hydrochloride 15 mg 
4 Rectal Morphine Hydrochloride 20 mg 
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3.3.1.1 Rectal morphine administration – a custom-designed approach 
The principal mechanism of drug absorption from the rectum is passive diffusion. Drug will be absorbed in 
the submucousal venous plexus, which is drained by the superior, the middle and the inferior rectal veins 
(91). In the upper rectum, the superior rectal vein drains via the portal system and morphine will undergo 
first-pass metabolism before entering the systemic circulation. The lower part of the rectum is drained by the 
middle and inferior veins, which drains into the systemic system via the internal iliac vein. However, as 
extensive anatomosis exits between these two systems, only a partial avoidance of hepatic first-pass 
metabolism can be achieved (92,93). Altogether these mechanisms were considered, when designing study I 
and II. In addition, to avoid adsorption of morphine to faeces, the participants had their bowels cleansed 
before drug administration. Drug administration was performed in the upper rectum, 20 cm from the anal 
verge. This site was preferable to the lower rectum, as morphine would go via the portal system before 
entering the systemic circulation and thereby, a wider “peripheral time frame” could be attained. The 
peripheral timeframe was defined as the timeframe from drug administration until the drug exerted a 
measurable effect mediated via the CNS. For drug administration, a custom-made rectal probe was 
developed for study I. The probe had a length of 25 cm and four lumens for medicine administration. In 
addition, one lumen contained a guide wire to stabilize the probe. The corresponding medicine outlets were 
positioned one cm below the tip of the probe. The probe enabled medication to be sprayed evenly onto the 
rectosigmoid wall.  
 
3.3.1.2 Population pharmacokinetic modelling 
Pharmacokinetics (PK) is the quantitative study of what the body does to a drug substance and describes the 
absorption, distribution, metabolism and elimination (rate processes) (94). In brief, a PK model describes the 
mathematical relationship between the administered dose and the observed drug concentration-time profiles 
in an individual. The concentration should ideally be measured at the effect site (biophase), where the 
interaction with the receptor system occurs. However, in general this is not possible when dealing with drugs 
which exert their effects within the CNS. Most often the concentration is measured in more easily accessibly 
body fluids such as blood as the case in the present study (95). The structure of a PK model can be illustrated 
by a diagram (boxes interconnected with arrows, see Fig. 6), which describes the rate of drug transfer 
between various compartments. Mathematically, the model can be described in terms of compartment 
volumes, clearances, rate constants etc. (94,95).                
    Analysis of PK data using a modelling approach is typically done by either an individual two-stage 
approach or a population approach, to describe typical parameters for the population and the variability. The 
population approach (also called non-linear mixed effect) has the strength of using all data simultaneously 
and thereby informing the model with each of the individual profiles to compute the typical population 
profile in addition to describing the variability in the data. Non-linear mixed effect modelling encompasses 
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fixed and random effects (95). Fixed effects are the typical parameters for the population (also called the 
structural model). Random effects describe the variability from the population mean, in terms of inter-
individual and inter-occasion variability in addition to remaining residual error in the model. Description of 
the population variability is important to identify factors (e.g. demographics or genetics) that may help 
understand why some patient subgroups differ in their clinical response from the ‘typical’ population. These 
factors are termed covariates in a population model.  To attain a sound description of the PK, it is essential to 
draw adequate blood samples during the time course (94). Each participant had one pre-dose and nine post-
dose blood samples drawn. The sampling times were chosen on the basis of the PK of a previous study of 
rectal liquid morphine administration (61). To obtain detailed temporal PK information a sampling matrix 
design was applied. According to the sampling matrix design, participants were allocated to individual blood 
sampling times. This resulted in the following post dose sampling intervals: 1-5 minutes, 6-10 minutes, 11-
15 minutes, 16-20 minutes, 22-30 minutes, 36-60 minutes, 66-90 minutes, 96-120 minutes and finally 130-
180 minutes (Table 3).  
 
Table 3: Overview of the applied sampling matrix. Each individual was identified by a unique identification number (ID) (001-010). 
Identification numbers are highlighted in black. The allocated individual sampling times (time 0-9) are given in minutes in the 
columns below the identification numbers. 
 SAMPLING MATRIX DESIGN 
ID 001 002 003 004 005 006 007 008 009 010 
Time 0 0 0 0 0 0 0 0 0 0 0 
Time 1 1 2 3 4 5 1 2 3 4 5 
Time 2 6 7 8 9 10 6 7 8 9 10 
Time 3 11 12 13 14 15 11 12 13 14 15 
Time 4 16 17 18 19 20 16 17 18 19 20 
Time 5 22 24 26 28 30 22 24 26 28 30 
Time 6 36 42 48 54 60 36 42 48 54 60 
Time 7 66 72 78 84 90 66 72 78 84 90 
Time 8 96 102 108 114 120 96 102 108 114 120 
Time 9 130 140 150 160 180 130 140 150 160 180 
 
Each participant had one blood sample drawn within each of the intervals. The time differentiation scheme 
allowed for additional points on the PK curve than if each participant had been allocated to the identical 
sampling times. NONMEM 7.2 (ICON Development Solutions, Hanover, Maryland, USA) were used for the 
population PK modelling. All intravenous and rectal serum concentration-time profiles of morphine and 
M6G were modelled simultaneously. For detailed information regarding the bioanalytical analysis and the 
population-PK analysis, the reader is referred to (I).  
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3.3.1.3 Subjective pain assessment 
Psychophysical methods can be applied to quantitatively assess pain perception in participants. They are 
based on the subjective pain experience and are measured by means of either standardized scales or as pain 
thresholds. A combined electronic visual analogue scale (VAS) for measurement of non-painful (0 to 5) and 
painful (5 to 10) sensations was used to assess the pain perception (Table 4). The VAS was combined with 
anchor words to describe the sensations: 0 = no perception, 1 = vague perception of mild sensation, 2 = 
definite perception of mild sensation, 3 = vague perception of moderate sensation, 4 = definite perception of 
moderate sensation, 5 = the pain threshold, 6 = mild pain. 7 = moderate pain, 8 = pain of medium intensity, 9 
= intense pain, and 10 = unbearable pain. The VAS has proven to be robust and valid in assessment of 
experimental somatic (96) and visceral pain (97). Moderate pain (VAS=7) was chosen as the stimulation 
endpoint for the thermal skin stimulation and the mechanical muscle stimulation. 
  
Table 4: The combined VAS with anchor words  
Combined VAS with anchor words 
0 No perception 
1 Vague perception of mild sensation 
2 Definite perception of mild sensation 
3 Vague perception of moderate sensation 
4 Definite perception of moderate sensation 
5 The pain threshold 
6 Mild pain 
7 Moderate pain 
8 Pain of medium intensity 
9 Intense pain 
10 Unbearable pain 
 
 
3.3.1.4 Pain stimulation  
The analgesic effect of morphine on two quantitative sensory testing measures, mechanical muscle 
stimulation and thermal skin stimulation was assessed in the present study. The purpose of this assessment 
was to evaluate which was the most sensitive to morphine analgesia and thus, which to be applied in study II.  
For both methods, stimulations were performed at baseline and eight times after dosing according to a matrix 
similar to the blood sampling matrix: This resulted in the following eight post dose pain stimulation 
intervals: 2-6 minutes, 8-12 minutes, 14-18 minutes, 21-25 minutes, 30-54 minutes, 60-84 minutes, 90-114 
minutes and 130-180 minutes. Stimulations were performed in the indicated order: 1) mechanical muscle 
stimulation and 2) thermal skin stimulation.  
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Mechanical muscle stimulation 
Pain from muscles is clinically manifested as a cramp-like, aching and diffuse sensation. It may also be 
associated with referred to other deep somatic tissue. Aδ- and C-fibers are primarily located in wall of 
arterioles of the muscle belly (98). Experimental muscle pain models can be divided into exogenous or 
endogenous models. In endogenous models the pain is induced by natural stimuli e.g. by exercise induced 
pain or ischemic pain whereas external pain stimuli (e.g. mechanical, electrical or chemical induced pain) is 
used in exogenous models (99,100). An exogenous model by means of the pneumatic tourniquet cuff (cuff) 
(101,102) was applied (Fig. 4). The cuff enabled mechanical stimulation of gastrocnemius muscle of the 
right leg with pressure being uniformly delivered to deep as well as superficial tissues. This stimulation 
method has successfully been employed in pharmacological testing (103,104) and has proven to be both 
reliable and sensitive (101).  
 
Thermal skin stimulation 
In most studies of analgesic actions, experimental models in skin have been used, which is likely due to the 
easy access (80). The skin is innervated by cutaneous nerve fibres sensitive to heat, cold, pressure, irritation, 
itch and pain. Cutaneous nociceptors are found in the dermis or epidermis and include Aδ- and C-fibers, 
although unmyelinated fibers accounts for approximately 90% of all cutaneous nerve fibers (105).  
    Thermal skin stimulation is one method and it can be performed by cold and heat pain. Heat pain was used 
in the present study and was performed by means of a heating thermode (TSA II, MEDOC, Ramat Yishai, 
Israel) sized 25x50 mm (Fig. 4). It was applied 10 cm from the elbow joint on the volar surface of the left 
forearm. Thermal stimulation can be achieved with a rapid or a slow rate. Heating with a slow rate of (1˚ C 
/sec) was used in the present study. The temperature increased from 32˚ C to 52˚ C. A temperature of 52˚ C 
was chosen as the stimulation endpoint due to safety reasons. The slow rate was used as it predominantly 
activates C-fibers (14) and consequently, is suitable for detection of opioid effects as it is the traditional 
opinion that opioid mainly attenuate C-fibre mediated pain (80).  
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Fig. 4: Experimental setup in study I. Study I was an open label, four-way study with escalating doses of morphine hydrochloride, at 
the first study visit 2 mg morphine hydrochloride was administered intravenously. The three consecutive study visits 10-, 15-, and 20 
mg morphine hydrochloride was administered rectally in ascending order by means of a custom-designed probe. Mechanical muscle 
stimulation was performed by means of a tourniquet cuff (right leg). Additionally, thermal skin stimulation was performed with a 
heating thermode. It was applied 10 cm from the elbow joint on the volar surface of the left forearm. The pain sensation was 
subjectively assessed with a VAS. In addition, PK blood sampling was performed. 
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3.3.1.5 Registration of adverse effects 
Morphine analgesia may be accompanied by several centrally mediated side effects as described in section 
1.3.1.2. The adverse effect profile following rectal administration of liquid morphine has to some degree 
been established in patients (59-61). This is best described in cancer patients following long-term treatment 
(60). The most pronounced symptoms were constipation, drowsiness, nausea, dry mouth and vomiting and 
6% of the patients had to discontinue rectal drug administration due to local intolerance. Administration of 
methylnaltrexone (study II) has been associated with gastrointestinal adverse effects. Altogether, the 
assessment of tolerability and safety is imperative in the study design. To assess safety and tolerability, the 
participants were asked to rate the following adverse effects: “nausea”, “dizziness”, “itching”, “sweating”, 
“sedation” and “lower gastrointestinal complaints” before dosing and 10, 20, 30, 45, 60, 90, 120 and 180 
minutes after dosing. Participants were asked to grade the severity of the adverse effects, if any (1=no 
effects, 2=modest effects, 3=moderate effects and 4=intolerable effects).  
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3.3.2 Key results  
3.3.2.1 Participants 
During the period of June 2012 to October 2012 ten males were screened. Their mean age was 25.6 years 
(range 23-29 years) and mean weight was 77.1 kg (range 63-100 kg). They all met the inclusion criteria and 
were enrolled in the study. Following rectal morphine administration no leakage was observed in any of the 
participants.  
 
3.3.2.2 Adverse effects and dose selection 
The majority of participants rated the adverse events as being modest. Two participants rated the adverse 
events as being of moderate nature (one after 10 mg morphine (nausea and “stomach rumble”) and one after 
20 mg morphine (dizziness) but none rated them as being intolerable and in addition, no local intolerance or 
other gastrointestinal complications were observed. The observed adverse effects appeared to be dose 
independent. As the highest dose (20 mg) was well tolerated, it was decided to further increase the dose in 
study II, as relative high doses are preferred when analgesic effects are investigated in experimental human 
pain studies (80). Pharmacokinetic-pharmacodynamic (PK-PD) modelling was used as a simulation tool. 
Simulations were based on data from mechanical muscle stimulation, as this quantitative sensory test proved 
to be more sensitive to morphine analgesia than thermal skin stimulation. Mechanical muscle stimulation 
was thus, to be used in study II (Fig. 5). During the simulations a dose of 30 mg morphine was found to 
provide an approximately 15% increase (from baseline) in tolerated muscle pressure (106).  
 
 
 
Fig. 5: Solid line represents data from 
the mechanical muscle stimulation and 
dotted line represents data from thermal 
skin stimulation. The pain stimulations 
were performed at baseline and eight 
times after dosing according to a matrix. 
This resulted in the following eight post 
dose pain stimulation intervals: 2-6 
minutes, 8-12 minutes, 14-18 minutes, 
21-25 minutes, 30-54 minutes, 60-84 
minutes, 90-114 minutes and finally 
130-180 minutes. 
 
Data were best described with a two compartment distribution model with one absorption transit 
compartment for rectal administration and systemic clearance from the central compartment (Fig. 6).  
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Fig. 6: Final PK model diagram for simultaneous description of serum concentration-time profiles of morphine (mor) and M6G 
following IV or rectal administration of morphine.  A is drug amount in the compartment and numbers denote the compartments (1: 
dosing; 2 and 3: the central and peripheral compartments of morphine; 4: morphine transit compartment from compartment 1 to 2; 5: 
central compartment of M6G; 6: transit compartment for M6G between compartment 2 and 5). Q3 is inter-compartmental clearance. 
V is volume of distribution. CLM6G is M6G clearance. ktr, ktr,M6G and ka are first-order rate constants between compartments, F rectal 
bioavailability and fadd is additional fraction of morphine converted to M6G after rectal administration. fM6G is fraction of total 
systemic morphine clearance converted to M6G. 
 
The mean morphine absorption transit time was 0.6 hours for a typical person (i.e. 70 kg) in the population. 
Clearance was 78 L/h (relative standard error (RSE) 12 %) and absolute bioavailability was estimated to 
24% (RSE 11%). Body weight was suggested to be an important covariate for morphine exposure.  
 
 
  
36 
 
3.4 Study II 
3.4.1 Methods 
Study II was designed as a randomized, placebo-controlled, double-dummy, double-blinded, four-way cross-
over study. Three of four treatment arms were intended for this Ph.D. project and is thus, described in this 
thesis (II, III). The forth treatment arm (low dose (0.2 mg) morphine hydrochloride) is to be included in 
future PK-PD studies.  
    Fifteen healthy male participants were to complete the study. As in study I, it was anticipated from clinical 
experience that morphine would have a lag-time of 30 minutes and that the peripheral effect of morphine 
therefore would be assessable within the first 30 minutes after administration. Thus, to assess the peripheral 
effects of morphine, pain stimulations were performed as frequent as possible within this “peripheral time 
frame”. Participants were randomised to three experimental sessions and received two different treatments 
during each visit: 1) subcutaneous MNTX 12 mg or matching placebo and 2) rectally administered morphine 
hydrochloride 30 mg or matching placebo giving rise to three different treatment scenarios: 1) 
placebo+placebo, 2) placebo+morphine hydrochloride 30 mg and 3) MNTX 12 mg mg+morphine 
hydrochloride 30 mg. According to the PK of MNTX (Tmax=0.5 hours), MNTX or matching placebo was 
administered 30 minutes prior to morphine administration in order to obtain maximal effect before morphine 
dosing. Administration was performed subcutaneously in the right thigh by one of the two research nurses. A 
washout period of minimum one week was left between the experiments. To reduce the nausea associated 
with the fast, intravenous administration of 5% glucose was started before initiation of each experiment.  
    In the remaining document, the placebo+placebo arm will be referred to as “placebo”, placebo+morphine 
hydrochloride 30 mg arm as “morphine” while the MNTX 12 mg mg+morphine hydrochloride 30 mg arm 
will be referred to as “MNTX/morphine”. Figure 8 outline the experimental setup.  
 
3.4.1.1 Pain stimulation 
The peripheral and central analgesic effect of morphine was assessed by means of mechanical rectal 
stimulation.  In study I, mechanical muscle stimulation proved to be more sensitive to morphine analgesia 
than thermal skin stimulation and was thus, used in the present study to assess the central analgesic effects of 
morphine. In addition, transcutaneous electrical stimulation was applied to assess the central analgesic 
effects.  
 
Visceral stimulation 
Experimental visceral pain models have been conducted in different parts of the GI tract (3,97,107). These 
models enable the investigator to stimulate and thus, activate specific groups of nociceptors in the gut. It is 
notable that these models are difficult to perform due to localization of the organs and the risk of organ 
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damage (107). Sensory information from the GI tract is mediated by either unmyelinated C-fibers (70-90%) 
or thinly myelinated Aδ-fibers (108). The proportion of C-fibers increases along the GI tract (from the oral to 
the anal end) and are localized in mucosa, muscle and serosa. The majority of the visceral nociceptors are 
polymodal thus, responding to an array of different stimuli (109). In rectal experimental studies, thermal, 
electrical and mechanical modalities have been applied (97,103,110-112). To assess the effect of morphine 
and MNTX on visceral pain, mechanical rectal stimulation by means of distension was performed. For this 
purpose, a rectal probe that allowed for both medicine administration and stimulation was developed. The 
design was based on the probe design applied in study I and the probe design of a multimodal rectal probe 
previously developed by our group (112). The probe designed for the present study had a length of 40 cm 
and had eight lumens. Two of these were intended for inflation and deflation, one for pressure recording, one 
contained a guide wire to stabilize the probe and essentially four for medicine administration (Fig. 7). 
 
 
 
 
 
 
 
Fig. 7: Schematic drawing of the probe applied in study II including the cross section of the probe (lower left hand side). The probe 
had a length of 40 cm and eight lumens. Two of these were intended for inflation and deflation of the non-compliant 30 µm thick 
polyestherurethane bag which was mounted 1.2 cm proximal to the probe tip. One lumen was intended for pressure recording, one 
contained a guide wire to stabilize the probe and essentially four for medicine administration. The medicine administration was 
performed 20 cm from the anal verge (20 cm marker). After drug administration the probe was withdrawn 5 cm and stimulations 
were performed with the probe placed 15 cm from the anal verge (15 cm marker).  
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The medicine administration was performed 20 cm from the anal verge. After drug administration the probe 
was withdrawn 5 cm. Distension was enabled via an inflatable non-compliant 30 µm thick poly-
estherurethane bag which was mounted 1.2 cm proximal to the probe tip (Fig. 7). Stimulations were 
performed with the probe placed 15 cm from the anal verge. The recorded pressure was used to monitor and 
control the quality of the distension. To precondition the tissue three distensions to the pain threshold (equal 
to VAS=5) were performed immediately prior to baseline (pre-dose) stimulation (78). Moderate pain 
(VAS=7) was chosen as the stimulation endpoint. Stimulations were made at baseline and at 1, 7, 15, 30, 60, 
120 and 180 minutes after drug administration. 
 
Somatic stimulation 
Mechanical muscle stimulation 
Mechanical muscle stimulation was performed (as described in section 3.3.1.4) at baseline and 1, 7, 15, 30, 
60, 120 and 180 minutes after dosing.  
 
Transcutaneous skin stimulation 
Transcutaneous electrical stimuli were applied using a commercially available, hand-held, constant current 
stimulator (PainMatcher®) (113). A constant current of 15 mA square wave pulses at 10 Hz was send 
through the tissue. The pulse duration (i.e. the electrical charge) was increased over time in increments of 4 
µsec, from 4 µsec to 396 µsec. Each increment corresponds to one step on an arbitrary scale from 0 to 99.  
In the assessment of transcutaneous electrical pain, the pain tolerance threshold (PTT) was applied. The PTT 
was defined as the maximum intensity of the electrical stimulus the participant was willing to accept in the 
given situation. The method was chosen on the basis of a previous study of morphine analgesia rendering 
significant results (114). PainMatcher® has proven to be reliable and reproducible (115,116) and in a 
practical context, the method could easily be implemented in the study design. Stimulations were made at 
baseline and at 1, 7, 15, 23, 30, 45, 60, 120 and 180 minutes after drug administration. 
 
 
 
 
39 
 
 
Fig. 8: Experimental setup in study II.  30 mg morphine hydrochloride or matching placebo was administered rectally by 
means of a custom-designed probe. The same probe allowed for mechanical stimulation of the rectum. The peripherally 
restricted µ-opioid antagonist, MNTX or matching placebo was administered subcutaneously in the left thigh. Mechanical 
muscle stimulation was performed by means of a cuff (right leg). Transcutaneous electrical stimulation was performed with 
Painmatcher® (right hand). The pain sensation was subjectively assessed with a VAS or with PTT (Painmatcher®). 
Centrally mediated effects were monitored with pupillometry and resting EEG. Additionally, prolactin and PK blood 
sampling was performed. The different measures were performed at baseline and at different times after drug 
administration and in the same order:  1. Blood sampling, 2. Pupillometry, 3. Resting EEG, 4. Mechanical rectal 
stimulation, 5. Mechanical muscle stimulation and 6. Transcutaneous electrical stimulation. To reduce the nausea 
associated with the fast, intravenous administration of 5% glucose was started before initiation of each experiment. 
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3.4.1.2 Objective assessments 
To objectively assess the impact of opioids in the CNS, pupillometry, prolactin concentration levels and 
resting EEG was used.  
 
Pupillometry 
Pupillometry is a method to measure the pupil diameter. Pupillary constriction can be induced following a 
sufficient dose of opioid agonists. Opioid induced pupillary constriction is also termed “opioid miosis”. The 
pupil diameter is regulated through interactions between the sympathetic and parasympathetic nervous 
systems. Pupillary constriction is mediated through the parasympathetic nervous system (117). However, the 
mechanisms behind opioid induced miosis remain unclear (118,119). The dominant theory is mainly based 
on canine studies (120,121). Theories have suggested that opioids directly stimulate the neurons in the 
pupilloconstrictor nucleus (Edinger-Westphal nucleus) (120,121) while others have suggested more indirect 
mechanisms (118,122). The pupil diameter is affected by lighting intensity (123). Indeed, Weinhold and 
Bigelow demonstrated that opioid induced miosis is best detected under moderately dimmed lighting 
conditions (123). In humans, opioid-induced miosis after administration of different opioids (e.g. morphine, 
tramadol, remifentanil and alfentanil) has been demonstrated under ambient lighting condition e.g. (69,124-
136) and pupillary response has become a well established objective index of central opioid effect.  For this 
reason, pupillometry was used for assessment of central morphine effect. The recordings were performed 
under moderately dimmed interior lighting conditions. To be able to manoeuvre in the laboratory during the 
experiment, the room was lit by 3 pc screens and a dimmed desk lamp. If the lighting conditions changed 
during the experiment a minimum of two minutes were allowed for dark adaptation before recording. 
Pupillometry recordings were performed using a commercially available digital infrared hand-held 
NeuroOptics VIP 200 pupillometer (NeuroOptics, Irvine, CA, USA) (137). Due to the non-invasive and 
painless character of the method, pupillary recordings were performed at baseline and intensively after 
dosing (1, 7, 15, 23, 30, 45, 60, 80, 100, 120 and 180 minutes). 
 
Prolactin 
It is well recognized that opioids generally stimulates the endocrine system (138) and it has been termed 
opioid endocrinopathy (45). The opioid induced hormonal effects have been documented in both men and 
women (138). Various studies, in both animals (138) and humans (139-142), have demonstrated the 
stimulant effect of morphine on prolactin secretion. In general, acute opioid administration stimulates 
prolactin secretion, while the effect of chronic opioid administration is less clear (138). It has been suggested 
that prolactin secretion is mediated via doperminergic neurons in hypothalamus (143). Therefore, prolactin 
plasma concentrations were used as a measure of opioid effect in the CNS. Consequently, serial blood 
sampling (baseline and 1, 7, 15, 23, 30, 45, 60, 120 and 180 minutes after dosing) was performed throughout 
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the study in order to evaluate the prolactin secretion. Prolactin concentrations were measured using an 
automated immunflourometric assay ((KRYPTOR) BRAHMS GmbH, Hennigsdorf, German) (144). The 
measurement principle is based on Time-Resolved Amplified Cryptate Emission (TRACE™) technology 
(144,145). In brief, the assay technology is based on non-radiating energy transfer between a donor (an 
Europium Cryptate labeled antibody) and an acceptor molecule (an XL665 labeled antibody). The donor and 
acceptor molecules bind to the prolactin (antigen) in the blood sample and form an immunocomplex 
(antibody-antigen-antibody complex). A nitrogen laser at 337 nm excites the donor which emits a fluorescent 
signal at 620 nm. The energy is transferred to the acceptor. The acceptor reemits a fluorescent signal at 665 
nm which is then measured. The fluorescence is proportional to the antigen (prolactin) concentration (144). 
 
Electroencephalography 
EEG is a non-invasive method that reflects the electrical activity in the brain over time. The activity can be 
recorded as spontaneous EEG or as evoked potentials after an external event such as a painful stimulus. 
Spontaneous EEG measures the neural activity at rest and was applied in the present study (146). The EEG 
recording is the sum of excitatory and inhibitory postsynaptic activities (147). These activities are 
synchronized in a large population of neurons in different brain regions and transmitted to the surface by 
volume conduction (148). The information contained in the raw EEG signal consists of a multitude of slow 
and rapid frequency potentials. Despite the chaotic nature, it has been demonstrated that EEG oscillates in 
distinct frequency bands (quantified by oscillations by second). The assessment of activity in each of the 
bands can be characterized by spectral analysis. In brief, by applying spectral analysis e.g. by means of 
traditional fourier transformation or the more advanced continuous wavelet transform, the raw EEG signal is 
transformed from the time domain into the frequency domain (146,149) (Fig. 9). The transformation results 
in a power spectrum which can be quantified into standardized frequency bands.  
    Spontaneous EEG has mainly been used to identify altered cerebral activity following pharmacological 
intervention with opioids and other centrally acting drugs (150). Collectively, quantitative EEG recordings in 
the context of drug testing are termed pharmaco-EEG (146,151,152). To quantify the effect of morphine on 
the resting EEG, the signals at vertex (Cz) were analyzed in terms of altered absolute and relative frequency 
distribution. The frequency distribution was retrieved by a continuous wavelet transform. The absolute 
distribution was divided in the following frequency bands: delta (0.5 – 3.5 Hz), theta (4 – 7.5 Hz), alpha1 (8 
– 10.5 Hz), alpha2 (10.5 – 13.5 Hz), beta1 (14.0 – 18.5 Hz), beta2 (19 – 24.5 Hz), and beta3 (25 – 32 Hz). 
The absolute distribution was used to calculate the relative distribution for each band as a percentage of the 
total power in the 0.5-32 Hz range. 
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Fig. 9: The parameterization of EEG activity is largely based on spectral analysis, by means of continuous wavelet transform. 
After digitalization, the EEG signal is transformed from the time domain into the frequency domain. The transform results 
in a power spectrum that is divided into four bands by frequency. The areas between the gray vertical lines denote the four 
frequency bands: delta (0.5–3.5 Hz), theta (4–7.5 Hz), alpha (8.0–13.5 Hz), and beta (14.0–32 Hz). 
 
 In pharmaco-EEG studies, opioids have generally induced a slowing of the spontaneous EEG seen as an 
increase of the activity in the delta band (153-156) (reviewed in reference (150)). However, increased 
activity in higher frequency bands have also been reported (154,157). EEG studies of morphine have 
produced contradicting results. As an example Lötsch and co-workers demonstrated an increase in the delta 
band (although the signal did fluctuate over time) and an increase in the alpha-1, beta-1 and beta-2 bands 
following intravenous morphine administration (157) while another study found no significant alterations in 
the spontaneous EEG after administration of intramuscular morphine (154). 
 
3.4.1.3 Registration of adverse effects 
Registration of adverse effects was performed as described in section 3.3.1.5 
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3.4.2 Key results 
3.4.2.1 Participants 
During the period of September 2013 to April 2014 nineteen males were screened. Of these, one did not 
meet the inclusion criteria due to addictive behaviour in a first degree relative. Thus, a total of eighteen 
participants enrolled in the study. Three of these participants withdrew their informed consent; one 
participant due to personal reasons and two participants due to unpleasantness during the study. 
Consequently, the study was completed by fifteen healthy male participants, mean age 25.5 years (range 20-
56) (Fig. 10).  
 
 
          
 
 
 
 
 
 
Fig. 10: Participant flow in study II. 19 healthy males were 
screened. Of these 18 was enrolled in the study. Three 
participants dropped out after inclusion, thus 15 participants 
completed the study. 
 
 
3.4.2.2 Study IIa 
No peripheral effect to rectal stimulation was found following morphine administration (P=0.8). In contrast, 
an effect was seen following MNTX/morphine administration (P<0.001). The effect was significantly 
different from placebo seven minutes after morphine administration and continued throughout the 
experiment. Morphine and MNTX/morphine both had an effect on mechanical muscle pressure (P<0.001, 
both treatments) and on pupil diameter (P<0.001, both treatments) compared to placebo. For both 
mechanical muscle pressure and pupil diameter, the effect occurred 30 minutes after dosing and the effect 
continued throughout the experiment. However, no change was observed in transcutaneous electrical 
stimulation following either morphine (P=0.8) or MNTX/morphine (P=0.6). One or more adverse effects 
were observed in 11 of 15 participants after administration of morphine, in 10 of 15 participants following 
MNTX/morphine administration and in 4 of 15 of the participants following placebo administration. No 
gastrointestinal adverse effects were recorded after MNTX/morphine administration. The majority of 
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participants rated the adverse effects as being modest. Only two participants rated the adverse effects as 
being of moderate nature but none rated them as being intolerable (II). 
 
3.4.2.3 Study IIb 
In addition to the effect on mechanical muscle pressure and on pupil diameter 30 minutes after dosing, 
morphine administration led to an increase in prolactin concentration (P<0.001) and also exerted an effect on 
the resting EEG, which was manifested as a decrease in the relative theta (4-7.5 Hz) activity (P=0.03). The 
increase in prolactin concentration became significant 45 minutes after administration (Fig. 11). The change 
in the relative theta activity was not significant until 120 minutes after dosing and did not correlate to the 
increase in tolerated muscle pressure (r=-0.1, P=0.43). On the other hand, the change in pupil diameter was 
negatively correlated to the change in tolerated muscle pressure (r=-0.40, P<0.001), whereas the increase in 
prolactin concentration was positively correlated (r=0.32, P=0.001) (III).  
 
 
 
 
 
 
 
Fig 11: Mean relative change (%) from baseline for 
tolerated muscle pressure, pupil diameter, prolactin 
concentration and relative theta activity. The curves 
represent the difference between morphine and placebo. 
Muscle pressure data, pupil diameter data and relative 
theta activity data are magnified to obtain values in the 
same range as prolactin concentration data (factors are 
shown in brackets).  
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4 Discussion 
4.1 Study I 
In the dose escalation study it was found that liquid morphine administered rectally is safe and well tolerated 
in healthy male participants in the dosage regime presented. Interestingly, the adverse effects did not appear 
to be dose dependent. Relative high doses are preferred when analgesic effects are investigated in 
experimental human pain studies (80) and an oral dose of 30 mg morphine has successfully been 
administered to healthy participants in various experimental pain studies (103,104,158). In the modelling of 
morphine serum concentrations after intravenous and rectal administration, the typical value of 
bioavailability was estimated to 24% for rectally administered morphine, which was found to be dose 
independent. After oral administration of a 12 mg morphine tablet, an absolute bioavailability of morphine 
has been reported to 20 ± 8.3% (159). Accordingly, morphine bioavailability after oral administration 
appears to be comparable with the bioavailability after rectal administration (I). The low bioavailability 
suggests that absorption from the upper part of the rectum is subject to extensive first-pass metabolism. 
Given that the 20 mg dose proved safe and well tolerated; and the population PK model further established 
that rectal absorption in the upper rectum is subject to extensive first-pass metabolism, it was decided to 
increase the dose to 30 mg in Study II. Mechanical muscle stimulation proved to be more sensitive to 
morphine analgesia than thermal skin stimulation. This is in good agreement with a recent population PK-PD 
modelling study suggesting that mechanical muscle stimulation is more clinically relevant for assessment of 
morphine pharmacodynamics than is thermal skin stimulation (160).   
    PK data was best described by a two compartment distribution model with one absorption transit 
compartment for rectal administration and systemic clearance from the central compartment. The structural 
model and typical parameter values for morphine’s systemic PK are comparable with those previously 
published using two-compartment models (161,162). Three-compartment models have also been presented 
for studies with longer sampling duration (163-165). Body weight was incorporated in the final model as 
allometric scaling of morphine’s systemic PK parameters. This finding indicates that clearance rates are 
perfusion-limited, which is in good agreement with the high extraction ratio evident by a systemic clearance 
value close to liver blood flow (~90 L/h for a 70 kg person) (166).  
    The present population PK model enabled assessment of variability components for the PK of a drug. For 
morphine, the absorption process appears to contribute the most to variability between participants and study 
occasion (IOV for ka and IIV for ktr). The variability in absorption suggested from the results of our study is 
in good agreement with the results from the study of Westerling et al. (61). It has been suggested that poor 
mucosal contact contributes to the large variation in both plasma concentration and bioavailability and that 
enhancement of contact between drug and mucosa will lead to a significant improvement in the inter-
individual variation (62). Another way to enhance the bioavailability of morphine may be to adjust the pH of 
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the solution. According to Moolenaar et al. adjustment to alkaline pH significantly increased the extent of 
morphine absorption (90).  
 
4.2 Study IIa  
Neither a central nor a peripheral analgesic effect to rectal stimulation was found following rectal morphine 
administration. As the method complied with all recommendations, there is no indication that the lack of 
effect was directly associated with the experimental procedures. There are different possible explanations to 
why no analgesic effect was observed following morphine administration: 1) It is well known that morphine 
generally increases rectal resting tone via effect in the enteric nervous system which will result in a less 
compliant rectum with poorer ability to accommodate volume (16). Thus, increased rectal tone may have 
distorted our ability to detect an analgesic effect of morphine on the rectal stimulation. 2) Although clinical 
studies have demonstrated peripheral mediated reduction in pain after local application of opioids, it has 
primarily been in the presence of inflammation and it has been shown that analgesic effect is less pronounced 
in non-inflamed tissue (33,34,104,167). The present experimental model was performed in non-inflamed 
tissue, which may partly explain the lack of a peripheral analgesic effect. 3) The κ-agonists have been 
suggested to be important modulators of visceral pain and that their effect is primarily mediated in the 
periphery (36,168). In visceral pain models in animals, κ-agonists have been suggested to be the most 
effective to attenuate visceral pain (38,39). This notion is further supported by findings from human 
experimental pain studies where oxycodone proved to be superior to morphine in alleviating visceral pain in 
both healthy participants and chronic pancreatitis patients (158,169). In contrast to morphine, oxycodone has 
shown an effect on κ-opioid receptors in animal studies (170-173). This indicates that oxycodone is a partial 
κ-agonist and it can be speculated that the affinity of κ-receptors may have contributed to the superior 
analgesic effect in these studies. It is plausible that only κ-agonists exert an effect on the peripheral afferents 
and thereby are a more effective class of opioids to alleviate visceral pain. 4) Another explanation could that 
µ-opioid receptors in the enteric nervous system may be a subgroup of opioid receptors, where binding of an 
agonist is mainly responsible for motility and not involved in nociception. 5) Although speculative, it could 
be hypothesized that MNTX administered systemically, will not reach the most peripheral gastrointestinal 
sensory afferents and thus, it will only block increased motility and not peripherally induced analgesia. This 
could explain why analgesia was seen as soon as seven minutes after administration of MNTX and 
morphine. This peripheral morphine analgesia may not be measurable after pure morphine administration as 
the effect of morphine on motility, will counteract the analgesia. Thus, according to the results from the 
present study, it cannot be excluded that morphine can exert a peripheral mediated analgesic effect. As 
aforementioned MNTX/morphine administration led to a significant increase in tolerated volume for rectal 
stimulation. Interestingly, the increase in tolerated volume became statistical significant only seven minutes 
after administration when compared to the morphine arm. This was unexpected since MNTX would enable 
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blockage of peripheral µ-opioid receptors and thus no effects of morphine would be expected within the 
peripheral timeframe (first 30 minutes). However, as speculated MNTX may not reach the most peripheral 
gastrointestinal sensory afferents and the effects seen, may be morphine analgesia. It may also be an effect of 
MNTX. MNTX antagonizes the effect of endogenous as well as exogenous opioids (16). Thus, blocking of 
opioid receptors in the enteric nervous system by MNTX may lead to a decreased rectal muscle tone (muscle 
relaxation). Supporting this, results from an animal study showed that naloxone, another opioid antagonist, 
decreased intraluminal pressure (174). This could explain the increased ability to accommodate more volume 
and the corresponding pain relief demonstrated in the present study. This suggests that MNTX does not 
counteract the potential peripheral analgesic effect of morphine on rectal pain but may on the contrary have 
an indirect analgesic effect on rectal distension. This is also in good agreement with results from a previous 
study where it was demonstrated that administration of butylscopolamine, a spasmolytic drug, abolished the 
hypersensitivity in patients with ulcerative colitis (175). This may reflect that opioid antagonists can alleviate 
gut pain related to distension rather than decreasing any potential local analgesic effect. Thus, the muscle 
relaxing effect of opioid antagonists may have a higher impact in visceral pain states, than previously 
assumed. 
    The dose of 30 mg morphine, estimated by simulations as described under study I, proved sufficient to 
induce central analgesia after rectal administration (II). The majority of participants experienced adverse 
effects after either morphine or MNTX/morphine administration. However, the adverse effects were 
primarily of modest nature which suggests that a 30 mg morphine solution, administered via the rectal route, 
is safe and well tolerated in healthy male participants. Central analgesia after either morphine or 
MNTX/morphine treatments was confirmed by attenuation of mechanical muscle pain and a decrease in 
pupil diameter. In both cases, the central analgesic effect was present 30 minutes after dosing and sustained 
throughout the study. The morphine induced miosis observed in the present study is in good agreement with 
previous studies of opioid induced miosis (124,126,129,130,133,135). After morphine administration, a 
maximum effect in tolerated muscle pain occurred after 60 minutes, where a 22% change from baseline was 
observed. This change is considerable higher than the initial target response of 15 %. The onset of central 
analgesia in the present study corresponds well with the onset of central analgesia after oral administration. 
On the other hand, none of the morphine treatments increased the sensory response to transcutaneous 
electrical stimulation, when compared to placebo. This is inconsistent with results from a previous study of 
Ravn et al. (114) where an increase in pain tolerance threshold following morphine administration were 
reported, when using Painmatcher®. However, differences in the study designs may account for the 
discrepancy. While a single rectal dose of 30 mg was administered in the present study, Ravn et al. 
administered low- and high dose morphine (10 mg and 20 mg, respectively) as intravenous infusions over a 
210 minute period. Considering the first-pass metabolism, the administered dose may have been too low to 
increase the sensory response to transcutaneous electrical stimulation.      
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4.3 Study IIb 
In addition to the decreased pupil diameter and increased muscle pain tolerance, morphine led to a significant 
increase in prolactin plasma concentration and a decrease in EEG oscillations in the relative theta band (III). 
Morphine had an effect on prolactin concentration 45 minutes after dosing and thus, shortly after subjective 
analgesia and pupillary response occurred. The time course of the increased prolactin concentrations 
observed after morphine administration corresponded reasonably well with the time course for central 
analgesia and results are consistent with results from previous studies on the effects of morphine on the 
endocrine system (139,141) (III).  
    In the present study both absolute and relative EEG activity was assessed. However, while no alterations 
were observed in any of the bands for the absolute distribution, a decrease in relative theta activity was seen. 
The decrease in relative theta activity, however, was not significant until 120 minutes after dosing and did 
not correlate to the mechanical muscle pain. Equivalent to the findings in the present study, decreased 
relative theta band activity has also been reported in a study on the frequency distribution after remifentanil 
infusion in healthy male participants (176). This could indicate that relative theta band oscillations, which are 
associated with the cortico-thalamic networks (10), are overruled by the electrical activity in other bands 
after opioid administration. The late onset of EEG alterations, 120 minutes after dosing, may be a result of 
relative short EEG segments (45 seconds) compared to traditional recordings of several minutes. In 
pharmaco-EEG studies, effects of opioids have traditionally been assessed by means of frequency 
distribution (150). In study II, the assessment of the frequency distribution was based on a single channel at 
the vertex which is a crude quantification of brain activity. Other analysis methods such as source 
localisation or network analysis may have be applied to gain increased insight to the cortical mechanism. 
However, due to the complexity in the methodologies they are not considered simple objective measures.   
     Both prolactin concentration and pupil diameter showed similar temporal development and both measures 
had good dynamic ranges. Additionally, both objective measures correlated to the subjective measure and 
thus, proved to be sensitive objective bed-side measures of morphine effect. However, from a practical and 
economical perspective, pupillometry is more feasible and is therefore recommended in experimental pain 
studies where simple objective assessments of the morphine effect are needed.  
 
4.4 Methodological considerations 
4.4.1 Study population 
In both study I and II healthy male participants aged 18-65 years were recruited. Females were disregarded 
due to logistical challenges and to save time. The nature of pain research and in particular research 
performed in the GI tract, will attract some individuals while fending off others. In addition, it tends to be 
less complicated to recruit students as they are more flexible time wise. By nature, students are generally in 
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their twenties. Only one out of 25 randomized participants (both studies) was middle aged; the remaining 
participants ranged between 18-29 years resulting in a homogenous group of healthy young male 
participants. Altogether, these methodological factors can lead to selection bias. Selection bias is inevitable 
in experimental pain research, particularly with respect to ethical considerations. Thus, the findings may not 
be generalized to the Danish population. However, the present Ph.D. project was conducted to increase 
knowledge about specific mechanisms and not to generalize to a certain population. On the other hand, the 
homogenous study population may have enhanced the internal validity. 
  
4.4.2 Rectal drug administration  
A high variability in absorption was seen after rectal administration in study I, which is consistent with 
previous findings (61,90). To facilitate a complete drug administration in study I and II, the rectal probe was 
perfused with 1 or 2 mL isotonic saline, respectively. Following administration no leakage was observed 
implying that the full dose was sufficiently administered. Body position and movement as well as individual 
rectal secretion are factors that may contribute to variability in absorption, as seen in the study I.  In study I 
the participants were asked to calmly sit upright immediately after drug administration. The movement and 
the influence of gravity may have contributed to spreading of morphine in the rectum, although it seems 
unlikely with a volume of only 6 ml (93). Nevertheless, in an attempt to improve the variability in 
absorption, the participants remained in the left lateral position after drug administration in study II. 
However, as population PK analysis for study II has not been performed up till now, the impact of this is yet 
to be seen. Variation in absorption caused by dysfunctional motility and adherence to faeces was considered 
negligible due to the fact that 1) the participants had normal bowel movements and 2) before initiation of 
each experiment the participants were given a bowel-cleansing enema.  
 
4.4.3 The experimental procedure 
Study II was double-blinded and thus, the investigators did not know the actual treatment allocation. 
However, when morphine or other opioids are administered in experimental pain studies, blinding can be 
difficult as CNS mediated adverse effects can be easily recognized in some participants and this may expose 
the treatment allocation both to the investigators and to the participants. This may have induced behavioral 
modifications in the participants in order to mirror the behaviour that they thought the investigator wished to 
see. On the other hand, the participants were informed that the long fast in combination with the lengthy and 
comprehensive experimental procedure was likely to cause tiredness and maybe even dizziness, thus cause 
effects similar to those experienced after administration of morphine. It is noteworthy that not all participants 
experienced adverse effects during the experimental session but in the proportion of participants who did, it 
may have induced bias the pain assessment. The effect of opioids is normally assessed by the subjective 
response to analgesia which may be confounded by several factors: 1) Repetitive stimuli can induce 
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sensitization (increased response) or habituation (decreased or ceased response) and have the potential to 
distort the pain assessment (177). In study II, habituation to muscle pressure stimuli was observed. However, 
as the study was placebo-controlled, the induced habituation did not affect the results on drug effects; 2) Pain 
is a subjective experience, which is influenced by various factors including anxiety and fear. Pain in patients 
is frequently associated with emotional distress, which can bias the pain perception. However, experimental 
pain assessment in healthy participants, as the case in study I and II, is less biased. 3) Subjective pain 
assessment requires full attention from the participant and opioid induced sedation and nausea could 
potentially influence the pain rating. In healthy participants however, it has been suggested that experimental 
pain may increase arousal levels and counteract the sedative effect accordingly (178). This notion was 
supported by results from an experimental pain study reporting an increased finger tapping frequency after 
both placebo and opioid administration suggesting an increased alertness (104). Regardless of these 
arguments it cannot be fully avoided that the subjective assessments of pain can be confounded.  
 
4.4.4 Study design 
Choice of study design was based on what would be best suited for addressing the objectives of this Ph.D. 
project. The project should be achievable within the three years available for a Ph.D. project, as well as 
adequately answering the research questions of this thesis with respect to validity and practicality. 
Experimental rectal pain can be evoked with different modalities (80). In our group thermal, electrical and 
mechanical methods have been established (111). However, due to the comprehensive testing regime in 
study II it was not possible to include more than one pain measure. Retrospectively, inclusion of more than 
one visceral pain measure may have enabled us to demonstrate peripheral morphine effects and thus, may 
have improved the study design. Along the same line, inclusion of a MNTX/placebo arm would undoubtedly 
have enabled a more precise assessment the effects of MNTX.  
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5 Conclusions 
The three studied doses proved to be safe and well tolerated. Morphine was absorbed with a bioavailability 
which corresponds well with the bioavailability seen after oral administration. Mechanical muscle 
stimulation proved to be more sensitive to morphine analgesia compared to thermal skin stimulation and a 
morphine dose of 30 mg was estimated to be optimal for the proceeding study. Thus, the findings enabled 
dose selection and quantitative sensory test optimization. In addition, a population PK model of liquid rectal 
morphine and M6G was developed. 
    No peripheral analgesic effect of morphine was found. On the other hand, MNTX may have exerted a 
local effect on rectal distensions and thereby appeared to improve analgesia. Methodological shortcomings in 
the experimental study design may have contributed to the lack of peripheral morphine analgesia and thus, a 
peripheral effect of morphine on rectal pain cannot be excluded. A dose of 30 mg rectal morphine did 
however prove to be adequate to induce centrally mediated analgesia. This was manifested as an increase in 
tolerance to mechanical muscle pressure, a decrease in pupil diameter and an increase in prolactin 
concentration. An effect was also seen on resting EEG. Although, morphine did induce an effect on resting 
EEG, it was not considered a sensitive measure of morphine as the effect was considerable delayed 
compared to the analgesic effect observed on mechanically evoked muscle pain. Thus, only pupil diameter 
and prolactin concentration proved to be sensitive objective measures of central morphine analgesia. From a 
practical and economical perspective, pupil diameter is recommended as an objective measure of morphine 
induced central activation when a simple measurement is needed.   
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6 Future perspectives  
It was not possible to demonstrate peripheral analgesic effects of morphine in study II. Methodological 
shortcomings in the experimental study design (e.g. increased tone and lack of inflammation) may have 
contributed to the lack of peripheral morphine effects. As resting tone is affected by morphine, it would be 
rational to investigate the peripheral effect of morphine on a rectal stimulation modality, where the 
physiology is not influenced by morphine. Such a method could be heat or electrical stimulation. Models 
where the cross-sectional area is computed should be included to address the morphine effects on tone and 
stiffness of the rectal wall. Additionally, as there is substantial evidence that peripheral opioid analgesia is 
enhanced in the presence of inflammation it would be equally rational to investigate the peripheral effect of 
morphine in an inflammatory visceral model. In previous preclinical and clinical studies, κ-agonists have 
proven to attenuate visceral pain and thus, it would be rational to compare the effects of morphine to those of 
a κ-agonist. Oxycodone is a widely used opioid in the clinic. Although oxycodone is only a partial κ-agonist, 
previous human experimental pain studies have demonstrated that oxycodone has a better analgesic profile in 
visceral pain after systemic administration. In future studies, the effects of oxycodone or novel κ-agonists 
should be compared to those of morphine. Considering the findings from study II, the effects of antagonists 
on the GI tract should be further addressed. To more precisely assess the contribution of MNTX, a pure 
MNTX arm should be included in a future study.  
    The PK samples attained in study II will, together with the PK and PD findings from both studies, be 
included in future PK/PD modelling. In addition to this, the forth treatment arm from study II will be 
included in the modelling. The purpose is to quantitatively link the objective markers of central opioid 
receptor activation with morphine plasma concentration and analgesia.  
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Table 1: Rectally administered liquid morphine in adults 
 
Authors Drug, dose, formulation & administration Design Bioavailability Comments 
Pannuti et al. 1982 (60) Morphine hydrochloride  
Rectal dose: 10 mg  
administered every 4 hrs by a insulin-type 
syringe w/rubber tube 
diluted in distilled H2O to a concentration of 5 
mg/ml 
 
N=37 cancer patients,  
18-75 yrs  
 
NA Enema twice a week if patients did 
not empty their bowels 
spontaneously. 
Two of 37 patients had to discontinue 
treatment due to local intolerance. 
Westerling et al.  1982 (61) Morphine chloride 10 mg/ml  
Rectal dose: 0,3 mg/kg (~15-27.9 mg) 
Administration w/special applicator, not 
described in details. 
N=21 patients undergoing 
surgery (F), 32-72 yrs 
Weight: 58-93 kg 
Rectal and intramuscular 
administration  
31 % (12%-61%) 
Determined in a subset 
of patients (n=6) who 
received an 
intramuscular 
morphine injection. 
Marked interindividual variation in 
plasma concentration. No information 
regarding bowel cleaning prior to the 
study. Adsorption to faeces may have 
contributed to large to interindividual 
variation. 
Moolenaar et al. 1985 (90) Morphine hydrochloride  
Rectal dose: 10 mg 
dissolved in  
1) 5 ml citrate phosphate buffer (pH=4.5) and  
2) 5 ml of solution adjusted to pH 7.4 
5 ml syringe w/ a plastic applicator tube 
  
N=7 (M+F), healthy 
participants, 21-26 yrs 
Rectal and oral administration 
(cross-over study) 
NA 
(only AUC given) 
Increase in absorption rate and 
bioavailability when adjusting pH to 
7.4. 
 
De Conno et al. 1995 (59) Morphine hydrochloride 
Rectal dose: 10 mg (for 2 days)  
Administration with a syringe  
N=34 cancer patients 
Rectal and oral administration 
(cross-over study) 
NA Liquid morphine is well absorbed 
Efficacy and safety comparable with 
oral morphine. 
Pain relief achieved faster and 
maintained better after rectal 
administration. 
AUC: Area under the curve   
%: Percent 
W/: With 
F: Female 
M: Male 
Yrs: Years 
Hrs: Hours 
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